GoodRx Holdings stock
GDRXNASDAQGoodRx Holdings, Inc., HealthcareISIN US38246G1085
58Score 58 out of 100, Neutral
Price and trend
89 / 100
Price history
+15% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 7.6% below its 52-week high. Largest decline in 6 years: 97% (October 2020 to February 2026).
Chart figures for advanced users
- SMA 50$3.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.87
- The lowest closing price of the last twelve months.
- Resistance$3.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GoodRx Holdings, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $1.2B, is number 14 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $796.85M (up 0.6% year on year) and earnings of $30.44M (up 85.7%).
- For fiscal 2026, analysts expect on average revenue of $799.58M (up 0.3%) and adjusted earnings per share of $0.30 (down 13.3%).
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 302 of 714 in Healthcare, median 53.
- The P/E is 75.2 (Medical (Healthcare Information Services) median 43, own median of recent years 70.6).
- Our model puts fair value at $5.99, with the price 39% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 56
- Below fair valuePrice 39% below the fair value of $5.99.Valuation 53
Weaknesses
- Margin may fall backOperating margin 11%, average of the prior years 0.2%, which ranged from −50.1% to 8.3%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.Profitability 36
- DilutionShare count up 30% since 2020.Capital allocation 59
- Interest barely coveredOperating profit covers interest only 2.3 times.Stability 45
Its standout strengths are technical analysis and momentum, while stability and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 57 to 58.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.28 and expensive above $9.98 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $9.97 (cash-flow model) and $2.01 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $5.22, at 8.9% it would be $7.07.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (43).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 1.8% on the twelve months before. Revenue has grown strongly since 2016, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating 11%, net 4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 5 Aug 2026EPS reported $0.08 (expected $0.08)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.300.0%
- Revenue
- $799.58M0.0%
- Earnings per share
- $0.350.0%
- Revenue
- $836.22M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +12.5%2026 guidance raised: revenue of $790 million to $805 million and adjusted EBITDA of $240 million to $250 million, with Pharma Direct growth raised from 50% to over 70%.
“Based on the strength of our operating performance, coupled with our continued focus on disciplined execution, we are also raising our adjusted EBITDA guidance to a range of $240 million to $250 million, underscoring our ability to drive profitable growth while continuing to invest in our strategic priorities.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $8.14M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GoodRx Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- Privia Health GroupPRVA $3.07B58
- CertaraCERT $1.79B54
- OmnicellOMCL $1.64B50
- Teladoc HealthTDOC $1.63B47
- Omada HealthOMDA $945.45M44
- HealthStreamHSTM $883.61M62
- PhreesiaPHR $795.13M55
- SOPHiA GENETICSSOPH $635.9M47
ETFs that hold GoodRx Holdings
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.37% | 0.68% | €5.31M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.00% | 0.35% | €8.19B |
Show 3 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.00% | 0.43% | €2.48B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.